Assessment of Respiration-Induced Motion and Its Impact on Treatment Outcome for Lung Cancer
Table 1
Patient and treatment characteristics of the 43 patients.
Factors
Characteristic
Number of cases
Percentage
Gender
Male
38
88.4%
Female
5
11.6%
Age (years old)
Median
56
Range
35–78
NSCLC
27
62.8%
Histology
SCLC
15
34.9%
Metastases
1
2.3%
I-II
2
7.4%
Stage of NSCLC ( = 27)
IIIA
5
18.5%
IIIB
15
55.6%
IV
5
18.5%
Stage of SCLC ( = 15)
Limited stage
15
100%
T1
10
23.8%
T status*
T2
7
16.7%
T3
7
16.7%
T4
18
42.8%
N0-1
5
11.9%
N status*
N2
16
38.1%
N3
21
50%
Left upper lobe
16
36.4%
Left lower lobe
1
2.3%
Tumor location†
Right upper lobe
17
38.6%
Right middle lobe
4
9.1%
Right lower lobe
6
13.6%
GTV volume (cm3)
Median
45
Range
0.5–454
Tumor attachment status†
Solitary tumor
14
31.8%
Attached tumor
30
68.2%
Median
62
Treatment dose of NSCLC (Gy) ( = 27)
Range
54–70
<60
6
22.2%
60–65
13
48.1%
66–70
8
29.6%
Treatment dose of SCLC ( = 15)
45
15
100%
Concurrent chemoradiotherapy*
NSCLC
24‡
88.9%
SCLC
15
100%
One nasopharyngeal carcinoma patient with isolated lung metastases was not included in the T or N status calculation. †One NSCLC patient had two lung lesions. ‡Two early patients received radiation alone. One locally advanced patient canceled chemotherapy for active tuberculosis. NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer; GTV: gross tumor volume.
